Heart, Lung and Circulation

Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services

Published:August 14, 2014DOI:
      Familial hypercholesterolaemia (FH) is the most common monogenic lipid disorder associated with premature coronary heart disease (CHD). However, the majority of people with FH are undiagnosed or undertreated. Early cholesterol lowering therapy reduces cardiovascular disease mortality in FH. Low awareness and knowledge of FH in specialty and general practice highlights the need for strategies to improve the detection and management of FH.
      We present an algorithm describing a multidisciplinary approach to FH detection and management. We highlight the role of primary care, and where GPs can work with preventive cardiologists to improve care of FH. Novel strategies to detect index cases with FH are presented including the community laboratory, highlighting patients at high risk of FH, and targeted FH detection through searching the general practice database.
      General practitioners request over 90% of LDL cholesterol measurements in the community. Once an individual with FH is detected only a small proportion of patients require specialty management with the majority of patients suitably managed in primary care. However, it is crucial to screen family members, as 50% of first-degree family members are expected to have FH due to the autosomal dominant inheritance.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Watts G.F.
        • Sullivan D.R.
        • Poplawski N.
        • van Bockxmeer F.
        • Hamilton-Craig I.
        • Clifton P.M.
        • et al.
        Familial hypercholesterolaemia: A model of care for Australasia.
        Atherosclerosis Supplements. 2011; 12: 221-263
        • Austin M.A.
        • Hutter C.M.
        • Zimmern R.L.
        • Humphries S.E.
        Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.
        Am J Epidemiol. 2004; 160: 407-420
        • Marks D.
        • Thorogood M.
        • Neil H.A.W.
        • Humphries S.E.
        A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
        Atherosclerosis. 2003; 168: 1-14
        • Soutar A.K.
        • Naoumova R.P.
        Mechanisms of Disease: genetic causes of familial hypercholesterolemia.
        Nat Clin Pract Cardiovasc Med. 2007; 4: 214-225
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • Ginsberg H.N.
        • Masana L.
        • Descamps O.S.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society.
        Eur Heart J. 2013; 34: 3478-3490
        • Pijlman A.H.
        • Huijgen R.
        • Verhagen S.N.
        • Imholz B.P.M.
        • Liem A.H.
        • Kastelein J.J.P.
        • et al.
        Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
        Atherosclerosis. 2010; 209: 189-194
        • Bender R.
        • Bell D.A.
        • Hooper A.J.
        • Edwards G.
        • van Bockxmeer F.M.
        • Watts G.F.
        • et al.
        Screening for familial hypercholesterolaemia.
        Pathology-Journal of the RCPA. 2012; 44: 122-128
        • Bell D.A.
        • Hooper A.J.
        • Bender R.
        • McMahon J.
        • Edwards G.
        • van Bockxmeer F.M.
        • et al.
        Opportunistic screening for familial hypercholesterolaemia via a community laboratory.
        Ann Clin Biochem. 2012; 49: 534-537
        • Kirke A.
        • Watts G.F.
        • Emery J.
        Detecting familial hypercholesterolaemia in general practice.
        Aust Fam Physician. 2012; 41: 965-968
        • Marks D.
        • Wonderling D.
        • Thorogood M.
        • Lambert H.
        • Humphries S.E.
        • Neil H.A.W.
        Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
        Health Technol Assess. 2000; 4: 1-123
        • Versmissen J.
        • Oosterveer D.M.
        • Yazdanpanah M.
        • Defesche J.C.
        • Basart D.C.G.
        • Liem A.H.
        • et al.
        Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
        Br Med J. 2008; 337: a2423
        • Sandhu M.S.
        • Waterworth D.M.
        • Debenham S.L.
        • Wheeler E.
        • Papadakis K.
        • Zhao J.H.
        • et al.
        LDL-cholesterol concentrations: a genome-wide association study.
        The Lancet. 2008; 371: 483-491
        • Kathiresan S.
        A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.
        N Engl J Med. 2008; 358: 2299-2300
        • Cohen J.C.
        • Boerwinkle E.
        • Mosley Jr., T.H.
        • Hobbs H.H.
        Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
        N Engl J Med. 2006; 354: 1264-1272
        • Ference B.A.
        • Yoo W.
        • Alesh I.
        • Mahajan N.
        • Mirowska K.K.
        • Mewada A.
        • et al.
        Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseA Mendelian Randomization Analysis.
        J Am Coll Cardiol. 2012; 60: 2631-2639
        • Goldberg A.C.
        • Hopkins P.N.
        • Toth P.P.
        • Ballantyne C.M.
        • Rader D.J.
        • Robinson J.G.
        • et al.
        Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
        J Clin Lipidol. 2011; 5: 133-140
        • Watts G.F.
        • Sullivan D.R.
        • van Bockxmeer F.M.
        • Poplawski N.
        • Hamilton-Craig I.
        • Clifton P.M.
        • et al.
        A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?.
        Heart Lung Circ. 2012; 21: 543-550
        • Bates T.R.
        • Burnett J.R.
        • van Bockxmeer F.M.
        • Hamilton S.
        • Arnolda L.
        • Watts G.F.
        Detection of familial hypercholesterolaemia: A major treatment gap in preventative cardiology.
        Heart Lung Circ. 2008; 17: 411-413
        • Dorsch M.F.
        • Lawrance R.A.
        • Durham N.P.
        • Hall A.S.
        Familial hypercholesterolaemia is underdiagnosed after AMI.
        Br Med J. 2001; 322: 111
        • Foody J.M.
        Familial Hypercholesterolemia: An Under-recognized but Significant Concern in Cardiology Practice.
        Clin Cardiol. 2013; 37: 119-125
        • Bairey Merz C.N.
        • Alberts M.J.
        • Balady G.J.
        • Ballantyne C.M.
        • Berra K.
        • Black H.R.
        • et al.
        ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease.
        J Am Coll Cardiol. 2009; 54: 1336-1363
        • Datta B.N.
        • McDowell I.F.
        • Rees A.
        Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia.
        Curr Opin Lipidol. 2010; 21: 366-371
        • Bell D.A.
        • Garton-Smith J.
        • Vickery A.
        • Kirke A.B.
        • Pang J.
        • Bates T.R.
        • et al.
        Familial Hypercholesterolaemia in Primary Care: Knowledge and Practices among General Practitioners in Western Australia.
        Heart Lung Circ. 2014; 23: 309-313
        • Krass I.
        • Walker A.T.
        • Watts G.F.
        Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?.
        International Journal of Clinical Pharmacy. 2012;
        • Benn M.
        • Watts G.F.
        • Tybjaerg-Hansen A.
        • Nordestgaard B.G.
        Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication.
        J Clin Endocrinol Metab. 2012; 97: 3956-3964
        • Law M.
        • Wald N.
        • Rudnicka A.
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003; 326: 1407-1408
        • Watts G.F.
        • Gidding S.
        • Wierzbicki A.S.
        • Toth P.P.
        • Alonso R.
        • Brown W.V.
        • et al.
        Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation.
        Int J Cardiol. 2014; 171: 309-325
        • McInnes D.K.
        • Saltman D.C.
        • Kidd M.R.
        General practitioners’ use of computers for prescribing and electronic health records: results from a national survey.
        Med J Aust. 2006; 185: 88
        • Morris J.K.
        • Wald D.S.
        • Wald N.J.
        The evaluation of cascade testing for familial hypercholesterolemia.
        American Journal of Medical Genetics Part A. 2011; 158: 78-84
        • Grieve F.
        • Plumb A.
        • Khan S.
        Radiology reporting: a general practitioner's perspective.
        Br J Radiol. 2010; 83: 17-22
        • Appleton C.A.
        • Caldwell G.
        • McNeil A.
        • Meerkin M.
        • Sikaris K.
        • Sullivan D.R.
        • et al.
        Recommendations for Lipid Testing and Reporting by Australian Pathology Laboratories.
        Clin Biochem Rev. 2007; 28: 32-45
        • Barlow I.M.
        Do interpretative comments influence patient management and do our users approve of the laboratory ‘adding on’requests? A follow-up General Practitioner and Nurse Practitioner survey.
        Ann Clin Biochem. 2009; 46: 85-86
        • Barlow I.M.
        Are biochemistry interpretative comments helpful? Results of a general practitioner and nurse practitioner survey.
        Ann Clin Biochem. 2008; 45: 88-90
        • Watts G.F.
        • Sullivan D.R.
        • van Bockxmeer F.M.
        • Poplawski N.
        • Hamilton-Craig I.
        • Clifton P.M.
        • et al.
        A Model of Care for Familial Hypercholesterolaemia: Key Role for Clinical Biochemistry.
        The Clinical Biochemist Reviews. 2012; 33: 25
        • Talmud P.J.
        • Shah S.
        • Whittall R.
        • Futema M.
        • Howard P.
        • Cooper J.A.
        • et al.
        Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
        The Lancet. 2013; 381: 13-19
        • Daniels S.R.
        • Gidding S.S.
        • de Ferranti S.D.
        Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
        J Clin Lipidol. 2011; 5 (S30–S7)
        • Martin A.C.
        • Coakley J.
        • Forbes D.A.
        • Sullivan D.R.
        • Watts G.F.
        Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care.
        J Paediatr Child Health. 2012; 49 (E263–E72)